Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial

[1]  Hyun Seung Kim,et al.  Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye , 2019, Korean journal of ophthalmology : KJO.

[2]  K. Yoon,et al.  Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial , 2019, BMC Ophthalmology.

[3]  H. Kim,et al.  Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. , 2018, International journal of ophthalmology.

[4]  S. Pflugfelder,et al.  The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. , 2017, Ophthalmology.

[5]  D. Schaumberg,et al.  Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. , 2017, American journal of ophthalmology.

[6]  K. Tsubota,et al.  Classification of Fluorescein Breakup Patterns: A Novel Method of Differential Diagnosis for Dry Eye. , 2017, American journal of ophthalmology.

[7]  D. Schaumberg,et al.  TFOS DEWS II Epidemiology Report. , 2017, The ocular surface.

[8]  K. Tsubota,et al.  TFOS DEWS II Definition and Classification Report. , 2017, The ocular surface.

[9]  J. Wolffsohn,et al.  TFOS DEWS II Diagnostic Methodology report. , 2017, The ocular surface.

[10]  Stefano Bonini,et al.  TFOS DEWS II pathophysiology report. , 2017, The ocular surface.

[11]  R. Dana,et al.  TFOS DEWS II Management and Therapy Report. , 2017, The ocular surface.

[12]  S. Kinoshita,et al.  The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjögren’s syndrome: a pilot study , 2016, Eye.

[13]  J. Chung,et al.  Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial. , 2016, American journal of ophthalmology.

[14]  Kyoung Lae Kim,et al.  Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery , 2016, Journal of ophthalmology.

[15]  Won Choi,et al.  Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye , 2015, Optometry and vision science : official publication of the American Academy of Optometry.

[16]  J. Baret,et al.  Stabilisers for water-in-fluorinated-oil dispersions: Key properties for microfluidic applications , 2015 .

[17]  L. Gong,et al.  Topical Fluorometholone Treatment for Ocular Dryness in Patients With Sjögren Syndrome , 2015, Medicine.

[18]  C. Hammond,et al.  Prevalence and risk factors of dry eye disease in a British female cohort , 2014, British Journal of Ophthalmology.

[19]  H. Hwang,et al.  Additive Effect of Preservative-free Sodium Hyaluronate 0.1% in Treatment of Dry Eye Syndrome With Diquafosol 3% Eye Drops , 2014, Cornea.

[20]  F. Vrečer,et al.  Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs , 2013, Acta pharmaceutica.

[21]  S. Amano,et al.  Topical diquafosol for patients with obstructive meibomian gland dysfunction , 2013, British Journal of Ophthalmology.

[22]  A. Thakur,et al.  Review Article NANOEMULSION IN ENHANCEMENT OF BIOAVAILABILITY OF POORLY SOLUBLE DRUGS: A REVIEW , 2013 .

[23]  K. Tsubota,et al.  Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. , 2012, Ophthalmology.

[24]  K. Tsubota,et al.  A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients , 2012, British Journal of Ophthalmology.

[25]  R. Dana,et al.  Dry eye disease: an immune-mediated ocular surface disorder. , 2012, Archives of ophthalmology.

[26]  Xinghuai Sun,et al.  A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[27]  L. Baiza-Durán,et al.  A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome , 2010, British Journal of Ophthalmology.

[28]  A. Czogalla,et al.  Oral cyclosporine A - the current picture of its liposomal and other delivery systems , 2008, Cellular & Molecular Biology Letters.

[29]  E. Donnenfeld,et al.  Evaluation of topical cyclosporine for the treatment of dry eye disease. , 2008, Archives of ophthalmology.

[30]  Martin Grueterich,et al.  The challenge of dry eye diagnosis , 2008, Clinical Ophthalmology.

[31]  S. Yalkowsky,et al.  Solubilization of cyclosporin A , 2001, AAPS PharmSciTech.

[32]  M. Smolek,et al.  Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry‐eye patients having laser in situ keratomileusis , 2006, Journal of cataract and refractive surgery.

[33]  H. Lee,et al.  Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. , 2006, Ophthalmology.

[34]  R. Gurny,et al.  Cyclosporine A delivery to the eye: a pharmaceutical challenge. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.